Paperpal Prime Logo

Alimentary Pharmacology and Therapeutics : Impact Factor & More

eISSN: 1365-2036pISSN: 0269-2813

Aims and Scope of Alimentary Pharmacology and Therapeutics

Alimentary Pharmacology & Therapeutics is a bimonthly peer-reviewed medical journal concerned with the effects of drugs on the human gastrointestinal and hepato-biliary systems, particularly with relevance to clinical practice. The journal publishes original papers concerned with all aspects of basic and clinical pharmacology, pharmacokinetics, and the therapeutic use of drugs in the alimentary tract including the liver, gall bladder, and pancreas. Its editors are J. M. Rhodes and C. W. Howden. Less

Key Metrics

CiteScore
15.2
H-Index
195
Impact Factor
5 - 10
Scite Index
0.85 5-Year SI
SJR
Q1Hepatology
SNIP
2.25
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on Alimentary Pharmacology and Therapeutics

Alimentary Pharmacology and Therapeutics Journal Specifications

Indexed in the following public directories

  • Web of Science Web of Science
  • Scopus Scopus
  • SJR SJR
Overview
Publisher WILEY
Language English
Frequency Semi-monthly
General Details
LanguageEnglish
FrequencySemi-monthly
Publication Start Year1987
Publisher URLVisit website
Website URLVisit website
View less

Planning to publish in Alimentary Pharmacology and Therapeutics ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Alimentary Pharmacology and Therapeutics

Letter: Calendar Era or Antiviral Choice-What Explains the Survival Benefit of Tenofovir Disoproxil Fumarate After Hepatocellular Carcinoma Resection?
  • 9 Aug 2026
  • Alimentary pharmacology & therapeutics
Letter: From End-Stage Renal Disease Association to Risk-Stratified Kidney Surveillance in Inflammatory Bowel Disease.
  • 9 Aug 2026
  • Alimentary pharmacology & therapeutics
Time to Positivity of a Rapid HBsAg Assay as a Surrogate Marker of Quantitative HBsAg: Multicentre Proof-of-Concept Study.
  • 6 Aug 2026
  • Alimentary pharmacology & therapeutics
Letter: Careful Interpretation of Lemborexant Efficacy and Safety in Patients With Cirrhosis. Authors' Reply.
  • 6 Aug 2026
  • Alimentary pharmacology & therapeutics
Letter: The Promotion of Lemborexant in Patients With Liver Cirrhosis and Insomnia-Limitations of Population Generalisation and Liver Safety.
  • 6 Aug 2026
  • Alimentary pharmacology & therapeutics
Letter: Sparse Mortality Events and the Apparent OS Benefit of TDF After HCC Resection. Authors' Reply.
  • 6 Aug 2026
  • Alimentary pharmacology & therapeutics
Letter: Calendar Era or Antiviral Choice-What Explains the Survival Benefit of Tenofovir Disoproxil Fumarate After Hepatocellular Carcinoma Resection?
  • 9 Aug 2026
  • Alimentary pharmacology & therapeutics
Letter: From End-Stage Renal Disease Association to Risk-Stratified Kidney Surveillance in Inflammatory Bowel Disease.
  • 9 Aug 2026
  • Alimentary pharmacology & therapeutics
Time to Positivity of a Rapid HBsAg Assay as a Surrogate Marker of Quantitative HBsAg: Multicentre Proof-of-Concept Study.
  • 6 Aug 2026
  • Alimentary pharmacology & therapeutics
Letter: Careful Interpretation of Lemborexant Efficacy and Safety in Patients With Cirrhosis. Authors' Reply.
  • 6 Aug 2026
  • Alimentary pharmacology & therapeutics
Letter: The Promotion of Lemborexant in Patients With Liver Cirrhosis and Insomnia-Limitations of Population Generalisation and Liver Safety.
  • 6 Aug 2026
  • Alimentary pharmacology & therapeutics
Letter: Sparse Mortality Events and the Apparent OS Benefit of TDF After HCC Resection. Authors' Reply.
  • 6 Aug 2026
  • Alimentary pharmacology & therapeutics

FAQs on Alimentary Pharmacology and Therapeutics